$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$ 🔺📈 🅱️U͎L͎L͎I͎S͎H͎📈🔺🗞️📰🚨Rumours of an acquisition/- partnership! Will u see it better than my initial target and reach $8⁉️🚀
H̤̮A̤̮P̤̮P̤̮Y̤̮ T̤̮R̤̮A̤̮D̤̮I̤̮N̤̮G̤̮ A̤̮H̤̮E̤̮A̤̮D̤̮! Cheers BC 📈🚀🍀🍀🍀
@Tiger_comments @Daily_Discussion @TigerPM @TigerWire @TigerPicks @TigerStars @TigerGPT @Kiwi_G @NightMorph
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Here is an analysis of Reviva Pharmaceuticals Holdings, Inc. (RVPH):
Business and Industry: Reviva Pharmaceuticals is a pharmaceutical company that focuses on developing and commercializing therapeutics for various diseases. The company operates in the healthcare sector and is part of the biotechnology industry. The healthcare sector is expected to experience steady growth in the future due to an aging population and increasing healthcare needs.
Earnings and Forecast: According to the latest earnings forecast, Reviva Pharmaceuticals is expected to report a loss per share of $0.95 for the fiscal year 2024. The forecast for fiscal year 2025 indicates a loss per share of $0.86. It's important to note that the forecasted earnings are negative, which implies that the company is not expected to be profitable in the near term.
Analyst Recommendation: Analysts have mixed opinions about Reviva Pharmaceuticals. Currently, there are 5 buy ratings and 1 hold rating on the stock.
Analyst Target Price: Based on the opinions of 5 analysts, the mean target price for Reviva Pharmaceuticals is $15.2, with a low target estimate of $14.0 and a high target estimate of $17.0. Please note that target prices are estimates and can vary among analysts.
Capital Flow Data: In the past 5 days, Reviva Pharmaceuticals has experienced negative capital flow. On December 6th, there was an inflow of 308.43 thousand units, followed by outflows on December 9th, 10th, 11th, and 12th. This indicates that investors have been selling more shares than buying.
Profiteer Ratio: The profiteer ratio for Reviva Pharmaceuticals as of December 12th is 0.5916.
Support and Resistance Price: The support and resistance prices for Reviva Pharmaceuticals as of December 12th are $1.732 and $2.992, respectively. These levels indicate the price range within which the stock has historically found support or faced resistance.
Stock Price: As of December 14th, the stock price of Reviva Pharmaceuticals is $2.8055.
Based on the information provided, it is important to note that stock prices can be influenced by various factors, including market conditions, company performance, and investor sentiment. The rumors of an acquisition/partnership could impact the stock price, but it's difficult to predict the exact outcome. The analyst target price provides a range of estimates, but it is important to conduct further research and analysis before making any investment decisions.
Please remember that this analysis is for informational purposes only and should not be considered as investment advice. Investing in stocks carries inherent risks, and it is advisable to consult with a financial advisor before making any investment decisions.
🔬🔬🔬 RVPH: Small-Cap, Big Potential 🚀
Reviva Pharmaceuticals ($RVPH) is on a mission to tackle some of the toughest challenges in healthcare. Analysts have set an ambitious price target of $15.20, representing a potential upside of 469.66% 📈💥.
🧠 Core Focus:
RVPH is advancing treatments for life-altering conditions such as:
• Schizophrenia
• Bipolar Disorder
• ADHD
• Major Depressive Disorder (MDD)
Who doesn’t know someone affected by one of these? For individuals and families dealing with ADHD, bipolar, or MDD, the need for better treatments is urgent. RVPH is working to close that gap.
💨 Respiratory Innovations:
Their breakthroughs don’t stop there. RVPH is also targeting respiratory diseases like:
• Pulmonary Hypertension
• Pulmonary Fibrosis
🗓 Catalysts Ahead:
With multiple milestones on the horizon, RVPH’s developments could make a significant impact, both in the market and for patients.
For a small-cap company, this is big work. Analyst confidence paired with real innovation? That’s worth watching 👀📊.
@Tiger_comments
🔬🔬🔬 RVPH: Small-Cap, Big Potential 🚀
Reviva Pharmaceuticals ($RVPH) is on a mission to tackle some of the toughest challenges in healthcare. Analysts have set an ambitious price target of $15.20, representing a potential upside of 469.66% 📈💥.
🧠 Core Focus:
RVPH is advancing treatments for life-altering conditions such as:
• Schizophrenia
• Bipolar Disorder
• ADHD
• Major Depressive Disorder (MDD)
Who doesn’t know someone affected by one of these? For individuals and families dealing with ADHD, bipolar, or MDD, the need for better treatments is urgent. RVPH is working to close that gap.
💨 Respiratory Innovations:
Their breakthroughs don’t stop there. RVPH is also targeting respiratory diseases like:
• Pulmonary Hypertension
• Pulmonary Fibrosis
🗓 Catalysts Ahead:
With multiple milestones on the horizon, RVPH’s developments could make a significant impact, both in the market and for patients.
For a small-cap company, this is big work. Analyst confidence paired with real innovation? That’s worth watching 👀📊.
@Tiger_comments
🔬🔬🔬 RVPH: Small-Cap, Big Potential 🚀
Reviva Pharmaceuticals ($RVPH) is on a mission to tackle some of the toughest challenges in healthcare. Analysts have set an ambitious price target of $15.20, representing a potential upside of 469.66% 📈💥.
🧠 Core Focus:
RVPH is advancing treatments for life-altering conditions such as:
• Schizophrenia
• Bipolar Disorder
• ADHD
• Major Depressive Disorder (MDD)
Who doesn’t know someone affected by one of these? For individuals and families dealing with ADHD, bipolar, or MDD, the need for better treatments is urgent. RVPH is working to close that gap.
💨 Respiratory Innovations:
Their breakthroughs don’t stop there. RVPH is also targeting respiratory diseases like:
• Pulmonary Hypertension
• Pulmonary Fibrosis
🗓 Catalysts Ahead:
With multiple milestones on the horizon, RVPH’s developments could make a significant impact, both in the market and for patients.
For a small-cap company, this is big work. Analyst confidence paired with real innovation? That’s worth watching 👀📊.
@Tiger_comments
🔬🔬🔬 RVPH: Small-Cap, Big Potential 🚀
Reviva Pharmaceuticals ($RVPH) is on a mission to tackle some of the toughest challenges in healthcare. Analysts have set an ambitious price target of $15.20, representing a potential upside of 469.66% 📈💥.
🧠 Core Focus:
RVPH is advancing treatments for life-altering conditions such as:
• Schizophrenia
• Bipolar Disorder
• ADHD
• Major Depressive Disorder (MDD)
Who doesn’t know someone affected by one of these? For individuals and families dealing with ADHD, bipolar, or MDD, the need for better treatments is urgent. RVPH is working to close that gap.
💨 Respiratory Innovations:
Their breakthroughs don’t stop there. RVPH is also targeting respiratory diseases like:
• Pulmonary Hypertension
• Pulmonary Fibrosis
🗓 Catalysts Ahead:
With multiple milestones on the horizon, RVPH’s developments could make a significant impact, both in the market and for patients.
For a small-cap company, this is big work. Analyst confidence paired with real innovation? That’s worth watching 👀📊.
@Tiger_comments
Great article, would you like to share it?
Great article, would you like to share it?
Great article, would you like to share it?
Great article, would you like to share it?
Great article, would you like to share it?